Adjuvant Nivolumab Beneficial in Esophageal, GE Junction Cancer
A study found that patients with gastroesophageal junction cancer who were treated with surgery and chemoradiotherapy had significantly longer disease-free survival if... Read More
Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy
A recent study found that patients over 70 with esophageal cancers benefited from “triple modality” surgery that included surgery, with five-year survival... Read More
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Merck received FDA approval for Keytruda plus chemotherapy for some patients with advanced esophageal or gastroesophageal junction cancer.
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
CARsgen Therapeutics was granted orphan drug designation by the US FDA for CAR-T Cells for the treatment of gastric and gastroesophageal junction... Read More
Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer
AstraZeneca and Daiichi Sankyo were granted priority review by the FDA for Enhertu to treat HER2-positive gastric or gastroesophageal junction cancer, with... Read More
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
The FDA granted fast-track designation to Leap Therapeutics’ DKN-01, which blocks the DKK1 protein found in abundance in some gastric tumors.
Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
In a trial, Bristol Myers Squibb’s Opdivo improved disease-free survival in patients with esophageal cancer who had undergone surgery and chemotherapy.
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
Five Prime Therapeutics’ investigational drug bemarituzumab showed promising efficacy in the late-line treatment of gastroesophageal junction adenocarcinoma.
BeiGene bags option on Leap cancer drug, requests PD-1 combination trial
BeiGene and Leap Therapeutics have teamed up to study a combination of an anti-DKK1 antibody with the anti-PD-1 antibody tislelizumab in patients... Read More
BeiGene bags option on Leap cancer drug, requests PD-1 combination trial
BeiGene and Leap Therapeutics have teamed up to study a combination of an anti-DKK1 antibody with the anti-PD-1 antibody tislelizumab in patients... Read More
